Tailoring biologic therapies for pediatric severe asthma: a comprehensive approach

Simple item page
dc.contributor.authorChaverri Repáraz, Claudia María
dc.contributor.authorLacalle Fabo, Esther
dc.contributor.authorErroz Ferrer, María
dc.contributor.authorGimeno-Castillo, María
dc.contributor.authorCastro-Garrido, Isabel
dc.contributor.authorIbarzabal-Arregi, Miren
dc.contributor.authorGonzález Arza, Nerea
dc.contributor.authorViguria, Natividad
dc.contributor.authorMoreno Galarraga, Laura
dc.contributor.departmentCiencias de la Saludes_ES
dc.contributor.departmentOsasun Zientziakeu
dc.date.accessioned2025-06-24T09:42:37Z
dc.date.available2025-06-24T09:42:37Z
dc.date.issued2025-01-27
dc.date.updated2025-06-24T09:39:01Z
dc.description.abstractIntroduction: Biologic therapies have revolutionized the management of severe asthma in pediatrics, offering targeted options for specific inflammatory pathways. This study aimed to review the current indications and availability of biologics approved for pediatric use as of January 2025 and to analyze the clinical experience of a tertiary center in managing this condition. Methods: A comprehensive review of the biologics available for treating severe asthma in children was conducted, highlighting their indications and key characteristics. Additionally, a retrospective analysis was conducted on the experience of the Pediatric Severe Asthma Unit at the University Hospital of Navarra in utilizing these therapies between 2015 and 2025, with a focus on treatment distribution and reasons for switching biologics. Results: As of January 2025, the biologics available for pediatric use include omalizumab, mepolizumab, dupilumab, tezepelumab, and benralizumab, each with specific indications and different administration profiles. At the analyzed center, the distribution of biologics was as follows: omalizumab (27%), mepolizumab (27%), dupilumab (37%), and tezepelumab (9%). At the same center, the biologic distribution 10 years earlier was 100% omalizumab. Therapy changes and switches were primarily related to clinical response, posology, and comorbidities. Conclusions: This study emphasizes the importance of individualized management in pediatric severe asthma, based on continuous evaluation and appropriate biologic selection according to the clinical characteristics of each patient. It also highlights the need to develop specific guidelines for adjusting, switching, and discontinuing these therapies.en
dc.format.mimetypeapplication/pdf
dc.identifier.citationChaverri Repáraz, C. M., Lacalle Fabo, E., Erroz Ferrer, M., Gimeno-Castillo, M., Castro-Garrido, I., Ibarzabal-Arregi, M., González Arza, N., Viguria, N., Moreno-Galarraga, L. (2025). Tailoring biologic therapies for pediatric severe asthma: a comprehensive approach. Children, 12(2), 1-12. https://doi.org/10.3390/children12020140.
dc.identifier.doi10.3390/children12020140
dc.identifier.issn2227-9067
dc.identifier.urihttps://academica-e.unavarra.es/handle/2454/54303
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofChildren (2025), vol. 12, núm. 2
dc.relation.publisherversionhttps://doi.org/10.3390/children12020140
dc.rights© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdolescentsen
dc.subjectBiologic therapiesen
dc.subjectChildrenen
dc.subjectIndividualized managementen
dc.subjectPediatric severe asthmaen
dc.titleTailoring biologic therapies for pediatric severe asthma: a comprehensive approachen
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication
relation.isAuthorOfPublicationcd85f9b5-fe76-479b-8881-2d15bf41cf53
relation.isAuthorOfPublication.latestForDiscoverycd85f9b5-fe76-479b-8881-2d15bf41cf53

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Chaverri_Tailoring.pdf
Size:
914.06 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Artículos de revista DCS - OZS Aldizkari artikuluak
Artículos de revista - Aldizkari artikuluak